Downregulation of phosphoglycerate kinase 1 by shRNA sensitizes U251 xenografts to radiotherapy

Cheng,Yi-Jun; Ding,Hao; Du,Hua-Qing; Yan,Hua; Zhao,Jin-Bing; Zhang,Wen-Bin; Zou,Yuan-Jie; Liu,Hong-Yi; Xiao,Hong

doi:10.3892/or.2014.3353

Downregulation of phosphoglycerate kinase 1 by shRNA sensitizes U251 xenografts to radiotherapy

Authors:
- Yi-Jun Cheng
- Hao Ding
- Hua-Qing Du
- Hua Yan
- Jin-Bing Zhao
- Wen-Bin Zhang
- Yuan-Jie Zou
- Hong-Yi Liu
- Hong Xiao
View Affiliations

Affiliations: Department of Neurosurgery, Nanjing Brain Hospital Affiliated to Nanjing Medical University, Nanjing, Jiangsu, P.R. China, Neuro-Psychiatric Institute, Nanjing Brain Hospital Affiliated to Nanjing Medical University, Nanjing, Jiangsu, P.R. China
Published online on: July 23, 2014 https://doi.org/10.3892/or.2014.3353
Pages: 1513-1520

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Phosphoglycerate kinase 1 (PGK1) has been demonstrated to be involved in radioresistance. The present study was designed to investigate the effect of PGK1 on the radioresistance in vivo. U251 glioma cells were transfected with the short hairpin RNA (shRNA)-PGK1 and pcDNA3.1-PGK1 using Lipofectamine 2000. The radiosensitivity of U251 xenografts was observed by tumor growth curve following radiotherapy. Quantitative PCR, western blot analysis and immunohistochemistry were performed to evaluate PGK1 expression in the xenografts from the different tumor models. The expression of PGK1 was maximally inhibited in response to shRNA4 at 24 h after the transfection in vitro. Tumor growth of the U251 xenografts was significantly inhibited following treatment with shRNA-PGK1 and radiotherapy. The expression of PGK1 in vivo at the mRNA and protein levels was downregulated by the treatment of shRNA1 when compared to levels following treatment with shNC and PBS after radiotherapy. The results showed that suppression of PGK1 enhanced the radiosensitivity of U251 xenografts and suggest that PGK1 may serve as a useful target in the treatment of radioresistant glioma.

View Figures

View References

1	De Witt Hamer PC, Robles SG, Zwinderman A, Duffau H and Berger M: Impact of intraoperative stimulation brain mapping on glioma surgery outcome: a meta-analysis. J Clin Oncol. 30:2559–2565. 2012.PubMed/NCBI
2	Smith JS, Chang EF, Lamborn KR, et al: Role of extent of resection in the long-term outcome of low-grade hemispheric gliomas. J Clin Oncol. 26:1338–1345. 2008. View Article : Google Scholar : PubMed/NCBI
3	Sanai N and Berger MS: Glioma extent of resection and its impact on patient outcome. Neurosurgery. 6:753–764. 2008. View Article : Google Scholar : PubMed/NCBI
4	Wen PY and Kesari S: Malignant gliomas in adults. N Engl J Med. 359:492–507. 2008. View Article : Google Scholar : PubMed/NCBI
5	Benjamin R, Capparella J and Brown A: Classification of glioblastoma multiforme in adults by molecular genetics. Cancer J. 9:82–90. 2003. View Article : Google Scholar : PubMed/NCBI
6	Behin A, Hoang-Xuan K, Carpentier AF and Delattre JY: Primary brain tumours in adults. Lancet. 361:323–331. 2003. View Article : Google Scholar : PubMed/NCBI
7	Höckel M, Schlenger K, Mitze M, Schäffer U and Vaupel P: Hypoxia and radiation response in human tumors. Semin Radiat Oncol. 6:3–9. 1996.
8	Unruh A, Ressel A, Mohamed HG, et al: The hypoxia-inducible factor-1α is a negative factor for tumor therapy. Oncogene. 22:3213–3220. 2003.
9	Ahmad SS, Glatzle J, Bajaeifer K, et al: Phosphoglycerate kinase 1 as a promoter of metastasis in colon cancer. Int J Oncol. 43:586–590. 2013.PubMed/NCBI
10	Chen G, Gharib TG, Wang H, et al: Protein profiles associated with survival in lung adenocarcinoma. Proc Natl Acad Sci USA. 100:13537–13542. 2003. View Article : Google Scholar : PubMed/NCBI
11	Zieker D, Königsrainer I, Tritschler I, et al: Phosphoglycerate kinase 1 a promoting enzyme for peritoneal dissemination in gastric cancer. Int J Cancer. 126:1513–1520. 2010.PubMed/NCBI
12	Wang J, Ying G, Wang J, et al: Characterization of phosphoglycerate kinase-1 expression of stromal cells derived from tumor microenvironment in prostate cancer progression. Cancer Res. 70:471–480. 2010. View Article : Google Scholar : PubMed/NCBI
13	Wang J, Wang J, Dai J, et al: A glycolytic mechanism regulating an angiogenic switch in prostate cancer. Cancer Res. 67:149–159. 2007. View Article : Google Scholar : PubMed/NCBI
14	Cecconi D, Palmieri M and Donadelli M: Proteomics in pancreatic cancer research. Proteomics. 11:816–828. 2011. View Article : Google Scholar : PubMed/NCBI
15	Lincet H, Guével B, Pineau C, et al: Comparative 2D-DIGE proteomic analysis of ovarian carcinoma cells: toward a reorientation of biosynthesis pathways associated with acquired platinum resistance. J Proteomics. 75:1157–1169. 2012. View Article : Google Scholar
16	Duan Z, Lamendola DE, Yusuf RZ, Penson RT, Preffer FI and Seiden MV: Overexpression of human phosphoglycerate kinase 1 (PGK1) induces a multidrug resistance phenotype. Anticancer Res. 22:1933–1941. 2002.PubMed/NCBI
17	Yan H, Yang K, Xiao H, Zou YJ, Zhang WB and Liu HY: Over-expression of cofilin-1 and phosphoglycerate kinase 1 in astrocytomas involved in pathogenesis of radioresistance. CNS Neurosci Ther. 18:729–736. 2012. View Article : Google Scholar : PubMed/NCBI
18	Ding H, Cheng YJ, Yan H, et al: Phosphoglycerate kinase 1 promotes radioresistance in U251 human glioma cells. Oncol Rep. 31:894–900. 2014.PubMed/NCBI
19	Wu W and Zhao S: Metabolic changes in cancer: beyond the Warburg effect. Acta Biochim Biophys Sin. 45:18–26. 2013. View Article : Google Scholar : PubMed/NCBI
20	Gatenby RA and Gillies RJ: Why do cancers have high aerobic glycolysis? Nat Rev Cancer. 4:891–899. 2004. View Article : Google Scholar : PubMed/NCBI
21	Seemann MD: PET/CT: fundamental principles. Eur J Med Res. 9:241–246. 2004.PubMed/NCBI
22	Zhang DH, Tai LK, Wong LL, Chiu LL, Sethi SK and Koay ES: Proteomic study reveals that proteins involved in metabolic and detoxification pathways are highly expressed in HER-2/neu-positive breast cancer. Mol Cell Proteomics. 4:1686–1696. 2005. View Article : Google Scholar : PubMed/NCBI
23	Luo FM, Liu XJ, Yan NH, et al: Hypoxia-inducible transcription factor-1α promotes hypoxia-induced A549 apoptosis via a mechanism that involves the glycolysis pathway. BMC Cancer. 6:262006.
24	Qing G, Skuli N, Mayes PA, et al: Combinatorial regulation of neuroblastoma tumor progression by N-Myc and hypoxia inducible factor HIF-1α. Cancer Res. 70:10351–10361. 2010.PubMed/NCBI
25	Aebersold DM, Burri P, Beer KT, et al: Expression of hypoxia-inducible factor-1α: a novel predictive and prognostic parameter in the radiotherapy of oropharyngeal cancer. Cancer Res. 61:2911–2916. 2001.
26	Ryan HE, Lo J and Johnson RS: HIF-1 alpha is required for solid tumor formation and embryonic vascularization. EMBO J. 17:3005–3015. 1998. View Article : Google Scholar : PubMed/NCBI
27	Lu H, Forbes RA and Verma A: Hypoxia-inducible factor 1 activation by aerobic glycolysis implicates the Warburg effect in carcinogenesis. J Biol Chem. 277:23111–23115. 2002. View Article : Google Scholar : PubMed/NCBI
28	Rodríguez-Enríquez S and Moreno-Sánchez R: Intermediary metabolism of fast-growth tumor cells. Arch Med Res. 29:1–12. 1998.
29	Hsu PP and Sabatini DM: Cancer cell metabolism: Warburg and beyond. Cell. 134:703–707. 2008. View Article : Google Scholar : PubMed/NCBI
30	Ward JF: Radiation mutagenesis: the initial DNA lesions responsible. Radiat Res. 142:362–368. 1995. View Article : Google Scholar : PubMed/NCBI
31	VandeBerg JL: The phosphoglycerate kinase isozyme system in mammals: biochemical, genetic, developmental, and evolutionary aspects. Isozymes Curr Top Biol Med Res. 12:133–187. 1985.PubMed/NCBI
32	Popanda O, Fox G and Thielmann HW: Modulation of DNA polymerases α, δ and ɛ by lactate dehydrogenase and 3-phosphoglycerate kinase. Biochim Biophys Acta. 1397:102–117. 1998.PubMed/NCBI
33	Vishwanatha JK, Jindal HK and Davis RG: The role of primer recognition proteins in DNA replication: association with nuclear matrix in HeLa cells. J Cell Sci. 101:25–34. 1992.PubMed/NCBI
34	McCord AM, Jamal M, Williams ES, Camphausen K and Tofilon PJ: CD133⁺ glioblastoma stem-like cells are radiosensitive with a defective DNA damage response compared with established cell lines. Clin Cancer Res. 15:5145–5153. 2009.
35	Narayana A, Gruber D, Kunnakkat S, et al: A clinical trial of bevacizumab, temozolomide, and radiation for newly diagnosed glioblastoma. J Neurosurg. 116:341–345. 2012. View Article : Google Scholar : PubMed/NCBI
36	Bao S, Wu Q, McLendon RE, et al: Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature. 444:756–760. 2006. View Article : Google Scholar : PubMed/NCBI
37	Zieker D, Bühler S, Ustündag Z, et al: Induction of tumor stem cell differentiation - novel strategy to overcome therapy resistance in gastric cancer. Langenbecks Arch Surg. 398:603–608. 2013. View Article : Google Scholar : PubMed/NCBI